Corporate Reputation of Pharma in Canada, 2023/2024: The Views of 100 Canadian Patient Groups - Fair Pricing Policies, Transparency of Pricing, and Engaging Patients in R&D Among the Lowest-Scoring Indicators
26 juin 2024 09h25 HE
|
Research and Markets
Dublin, June 26, 2024 (GLOBE NEWSWIRE) -- The "The Corporate Reputation of Pharma in 2023/2024 - The Patient Perspective - Canada Edition - The Views of 100 Canadian Patient Groups" report has been...
Corporate Reputation of Pharma in 2023/2024: The Patient Perspective and Views of 2,500+ Patient Groups - Pharma Corporate Reputation Falls from COVID Highs
26 juin 2024 06h51 HE
|
Research and Markets
Dublin, June 26, 2024 (GLOBE NEWSWIRE) -- The "The Corporate Reputation of Pharma in 2023/2024: The Patient Perspective (Global Edition) - The Views of 2,500+ Patient Groups Worldwide" report has...
Patient Perspective of 520 Cancer Patient Groups on the Corporate Reputation of Pharma in 2023/2024: Roche Ranked 1st, AstraZeneca Ranked 2nd, and Pfizer Ranked 3rd
21 juin 2024 08h54 HE
|
Research and Markets
Dublin, June 21, 2024 (GLOBE NEWSWIRE) -- The "The Corporate Reputation of Pharma in 2023/2024 - The Patient Perspective - Cancer Edition - The Views of 520 Cancer Patient Groups" report has been...
The Views of 103 Italian Patient Groups on the Corporate Reputation of Pharma, 2021-2022: Roche Ranked 1st Overall with Novo Nordisk in 2nd and Pfizer in 3rd
12 janv. 2023 08h53 HE
|
Research and Markets
Dublin, Jan. 12, 2023 (GLOBE NEWSWIRE) -- The "The Corporate Reputation of Pharma in 2021 - The Patient Perspective - Italy Edition: The Views of 103 Italian Patient Groups" report has been added to...
Patient Perspective of 151 German Patient Groups on the Corporate Reputation of Pharma, 2021-2022: Ranking of 24 Companies
12 janv. 2023 06h38 HE
|
Research and Markets
Dublin, Jan. 12, 2023 (GLOBE NEWSWIRE) -- The "The Corporate Reputation of Pharma in 2021- The Patient Perspective - Germany Edition - The Views of 151 German Patient Groups" report has been added...
Views of 258 Neurology Patient Groups on the Corporate Reputation of Pharma in 2022: Roche Ranked 1st, Novartis Ranked 2nd and Biogen Ranked 3rd
12 janv. 2023 06h28 HE
|
Research and Markets
Dublin, Jan. 12, 2023 (GLOBE NEWSWIRE) -- The "The Corporate Reputation of Pharma in 2022 - The Patient Perspective - Neurology Edition: The Views of 258 Neurology Patient Groups" report has been...
The Views of 300 Asian Patient Groups on the he Corporate Reputation of Pharma, 2021-2022: Overall Gilead Sciences Ranked 1st, Pfizer Ranked 2nd, and ViiV Healthcare Ranked 3rd
12 janv. 2023 06h23 HE
|
Research and Markets
Dublin, Jan. 12, 2023 (GLOBE NEWSWIRE) -- The "The Corporate Reputation of Pharma in 2021 - The Patient Perspective - Asia Edition - The Views of 300 Asian Patient Groups" report has been added to ...
The Views of 109 French Patient Groups on the Corporate Reputation of Pharma in 2021-2022: Amgen, Mylan, Eli Lilly, MSD, and Boehringer Ingelheim Witnessed the Biggest Rise in Rankings
12 janv. 2023 06h18 HE
|
Research and Markets
Dublin, Jan. 12, 2023 (GLOBE NEWSWIRE) -- The "The Corporate Reputation of Pharma in 2021- The Patient Perspective - France Edition - The Views of 109 French Patient Groups" report has been added to...
Corporate Reputation of Pharma Companies in Spain, 2020 vs 2021: ViiV Healthcare Ranked 1st, Janssen Ranked 2nd, Gilead Sciences Ranked 3rd
09 janv. 2023 08h48 HE
|
Research and Markets
Dublin, Jan. 09, 2023 (GLOBE NEWSWIRE) -- The "The Corporate Reputation of Pharma in 2021 - The Patient Perspective - Spain Edition: The Views of 154 Spanish Patient Groups" report has been added to...
Autoimmune Patient Perspective on the Corporate Reputation of Pharma Companies, 2021-2022: Focus on Innovation and Treatments, COVID-19, & Pricing and Access to Medicines
09 janv. 2023 08h28 HE
|
Research and Markets
Dublin, Jan. 09, 2023 (GLOBE NEWSWIRE) -- The "The Corporate Reputation of Pharma in 2021- The Patient Perspective - Autoimmune Edition - The Views of 293 Patient Groups (138 of these respondent...